About The Study: In patients with cardiometabolic heart failure with preserved ejection fraction, semaglutide and tirzepatide showed more than 40% risk reduction for the composite of hospitalization for heart failure or all-cause mortality compared with a placebo proxy. Tirzepatide showed no meaningful benefit over semaglutide.
Corresponding Author: To contact the corresponding author, Nils Krüger, MD, email nkruger1@bwh.harvard.edu .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.14092?guestAccessKey=604055a2-ce86-4984-8c53-11e9184281a1&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=083125
JAMA
31-Aug-2025